Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873134 | 0.88 | POLB (0.58) | POLBALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL14413332 | 0.84 | GAA (0.60) | POLBGAAALDH1A1LMNAKDM4E | |
| SCHEMBL13873385 | 0.79 | POLB (0.67) | POLBGAAALDH1A1LMNAKDM4E | |
| SCHEMBL13873125 | 0.78 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ASMN1; SMN2TSHR | |
| SCHEMBL13873102 | 0.74 | ALDH1A1 (0.66) | POLBALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2472949 | 0.74 | KMT2A (0.76) | POLBGAAALDH1A1LMNAKDM4E | |
| SCHEMBL28351204 | 0.72 | ALDH1A1 (0.69) | POLBGAAALDH1A1LMNAKDM4E | |
| SCHEMBL17140257 | 0.72 | KEAP1 (0.51) | POLBALDH1A1LMNAL3MBTL1MAPK1 | |
| SCHEMBL27035912 | 0.70 | KEAP1 (0.49) | POLBLMNA | |
| SCHEMBL14342789 | 0.70 | GAA (0.58) | POLBGAAALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | POLB 1775/4885GAA 735/4885ALDH1A1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.